ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 92 filers reported holding ASCENDIS PHARMA A/S in Q1 2018. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $54,521,000 | -58.4% | 473,475 | -63.9% | 1.25% | -66.2% |
| Q1 2019 | $131,064,000 | +107.9% | 1,313,328 | +24.8% | 3.70% | +54.1% |
| Q4 2018 | $63,043,000 | -17.1% | 1,052,647 | -1.9% | 2.40% | +18.1% |
| Q3 2018 | $76,008,000 | +6.5% | 1,072,647 | 0.0% | 2.03% | +8.6% |
| Q2 2018 | $71,352,000 | +11.0% | 1,072,647 | +9.2% | 1.87% | +3.9% |
| Q1 2018 | $64,265,000 | +36414.2% | 982,647 | +9726.5% | 1.80% | +16263.6% |
| Q2 2015 | $176,000 | +1.1% | 10,000 | 0.0% | 0.01% | -21.4% |
| Q1 2015 | $174,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |